Therapeutics /

Oncology

Our alliance with Guardant Health supports precision oncology, offering advanced tools like Guardant360® Liquid Biopsy and Guardant Reveal™ for personalized cancer care. These technologies provide non-invasive mutation profiling and early detection, empowering proactive and targeted treatment.

Partner

A Trusted Partner for Precision Oncology

Guardant Health is a pioneer in liquid biopsy technology, a non-invasive method of detecting cancer by analysing circulating tumor DNA (ctDNA) in blood. The company's mission is to improve the lives of cancer patients by enabling earlier detection, more accurate diagnosis, and more effective treatment.


Compai is proud to announce its partnership with Guardant Health, a leading precision oncology company dedicated to transforming cancer care. This collaboration brings Guardant Health's innovative products to Malaysia, offering patients and healthcare providers access to advanced diagnostic tools for early detection, accurate diagnosis, and personalized treatment.


Circulating tumor DNA (ctDNA) is a groundbreaking biomarker that allows for the detection of cancer through a simple blood sample. ctDNA consists of tiny fragments of DNA shed by cancer cells into the bloodstream. By analyzing ctDNA, we can detect mutations and genetic changes associated with specific cancers, enabling earlier detection and personalized treatment strategies.

Non-Invasive

No need for invasive tissue biopsies, making testing more accessible and less painful.

Early Detection

Identify cancer at its earliest stages, even before symptoms appear.

Precision Treatment

Tailor treatment plans based on specific genetic profiles of the cancer.

Ongoing Monitoring

Track how a cancer responds to treatment and detect recurrence promptly.

Non-Invasive

No need for invasive tissue biopsies, making testing more accessible and less painful.

Early Detection

Identify cancer at its earliest stages, even before symptoms appear.

Precision Treatment

Tailor treatment plans based on specific genetic profiles of the cancer.

Ongoing Monitoring

Track how a cancer responds to treatment and detect recurrence promptly.